OBJECTIVES: The purpose of this study was to determine whether @entity1924 reduces intimal @entity1373 in @entity1 undergoing long @entity17650 -eluting stent implantation (stent length: >=  30 mm) for native long coronary lesions (length: >=  25 mm). BACKGROUND: @entity256 after drug-eluting stent implantation remains a significant clinical problem in long coronary lesions. METHODS: @entity1 (n = 499) were assigned randomly to triple ( @entity117 , @entity1397 , and @entity1924 , triple group: n = 250) or dual antiplatelet therapy ( @entity117 and @entity1397 and placebo, dual group: n = 249) for 8 months after long @entity17650 -eluting stent implantation. The primary end point was in-stent late loss at the 8-month angiography according to the intention-to-treat principle. RESULTS: The 2 groups had similar baseline characteristics. The in-stent (0.56    0.55 mm vs. 0.68    0.59 mm, p = 0.045) and in-segment (0.32    0.54 mm vs. 0.47    0.54 mm, p = 0.006) late loss were significantly lower in the triple versus dual group, as were 8-month in-stent @entity256 (10.8% vs. 19.1%, p = 0.016), in-segment @entity256 (12.2% vs. 20.0%, p = 0.028), and 12-month ischemic-driven @entity75 revascularization (5.2% vs. 10.0%, p = 0.042) rates. At 12 months, major adverse @entity299 including @entity204 , @entity583 , and ischemic-driven @entity75 revascularization tended to be lower in the triple group than the dual group (7.2% vs. 12.0%, p = 0.07). Percent intimal @entity1373 volume by volumetric intravascular ultrasound analysis was reduced from 27.1    13.2% for the dual group to 22.1    9.9% for the triple group (p = 0.017). CONCLUSIONS: @entity1 receiving triple antiplatelet therapy after long @entity17650 -eluting stent implantation had decreased extent of late luminal loss, percent intimal @entity1373 volume, and @entity256 , resulting in a reduced risk of 12-month @entity75 revascularization compared with @entity1 receiving dual antiplatelet therapy. (Triple Versus Dual Antiplatelet Therapy after @entity17650 -Eluting Stent; NCT00589927).

A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce @entity256 after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-Eluting Stenting Followed by @entity1924 Treatment Reduces Late XXXX in @entity1 with Long Coronary Lesions) trial.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity17650 :: ('MESH:C489443', 'Chemical') :: ['ABT578', 'zotarolimus'] @entity75 :: ('MESH:D001927', 'Disease') :: ['target lesion'] @entity1397 :: ('MESH:C055162', 'Chemical') :: ['clopidogrel'] @entity1373 :: ('MESH:D006965', 'Disease') :: ['hyperplasia'] @entity117 :: ('MESH:D001241', 'Chemical') :: ['aspirin'] @entity256 :: ('MESH:D023903', 'Disease') :: ['restenosis', 'angiographic restenosis', 'Restenosis'] @entity1924 :: ('MESH:C045645', 'Chemical') :: ['cilostazol'] @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac events'] @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death']
@entity256 :: (MESH:D023903,Disease) :: ['Restenosis']
